214 related articles for article (PubMed ID: 694476)
1. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
Widström O; Kockum C; Nilsson BS
Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
[TBL] [Abstract][Full Text] [Related]
2. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Mombelli G; Monotti R; Haeberli A; Straub PW
Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
[TBL] [Abstract][Full Text] [Related]
4. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M
J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002
[TBL] [Abstract][Full Text] [Related]
5. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
6. [Biological significance of fibrinopeptide A elevation in the blood].
Mombelli G; Hofmann V; Straub PW
Schweiz Med Wochenschr; 1977 Dec; 107(48):1779-81. PubMed ID: 579262
[TBL] [Abstract][Full Text] [Related]
7. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
[TBL] [Abstract][Full Text] [Related]
8. In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer.
McCulloch P; Douglas J; Lowe GD; Murray G; George WD
Thromb Haemost; 1989 Apr; 61(2):318-21. PubMed ID: 2749603
[TBL] [Abstract][Full Text] [Related]
9. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease.
Yoda Y; Abe T
Thromb Haemost; 1981 Dec; 46(4):706-9. PubMed ID: 7330820
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen survival and fibrinopeptide A in acute leukemia.
Castaman G; Galloni E; Dri AV; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):52-6. PubMed ID: 8039760
[TBL] [Abstract][Full Text] [Related]
11. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma.
Koppert PW; Kuipers W; Hoegee-de Nobel B; Brommer EJ; Koopman J; Nieuwenhuizen W
Thromb Haemost; 1987 Feb; 57(1):25-8. PubMed ID: 2438796
[TBL] [Abstract][Full Text] [Related]
12. Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders.
Werle B; Sauckel K; Nathanson CM; Bjarnadottir M; Spiess E; Ebert W; Abrahamson M
Biol Chem; 2003 Feb; 384(2):281-7. PubMed ID: 12675521
[TBL] [Abstract][Full Text] [Related]
13. Fibrinopeptide A in liver cirrhosis: evidence against a major contribution of disseminated intravascular coagulation to coagulopathy of chronic liver disease.
Mombelli G; Fiori G; Monotti R; Haeberli A; Straub PW
J Lab Clin Med; 1993 Jan; 121(1):83-90. PubMed ID: 8426084
[TBL] [Abstract][Full Text] [Related]
14. [Interaction of fibrinogen with two forms of fibrin differing in the degree of activation by thrombin].
Belitser VA; Lugovskoĭ EV; Ugarova TP; Derzskaia SG
Biokhimiia; 1985 Aug; 50(8):1336-41. PubMed ID: 4074798
[TBL] [Abstract][Full Text] [Related]
15. [Gas analysis and pH-measurements in pleural effusions (author's transl)].
Szüle P; Wollák A
Z Erkr Atmungsorgane; 1981; 156(1):40-3. PubMed ID: 6784360
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of reactivity to airborne and food allergens in cutaneous vasculitis by variations in fibrinopeptide A and other blood coagulation, fibrinolysis and complement parameters.
Theorell H; Blombäck M; Kockum C
Thromb Haemost; 1976 Dec; 36(3):593-604. PubMed ID: 1037153
[TBL] [Abstract][Full Text] [Related]
17. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
Gadducci A; Baicchi U; Marrai R; Del Bravo B; Fosella PV; Facchini V
Gynecol Oncol; 1994 Jun; 53(3):352-6. PubMed ID: 8206409
[TBL] [Abstract][Full Text] [Related]
19. Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion.
Agrenius V; Chmielewska J; Widström O; Blombäck M
Am Rev Respir Dis; 1989 Nov; 140(5):1381-5. PubMed ID: 2817601
[TBL] [Abstract][Full Text] [Related]
20. [Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases].
Farbiszewski R
Postepy Hig Med Dosw; 1984; 38(2):133-55. PubMed ID: 6393101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
